Anti-Human CD2 (LO-CD2a) – Dylight® 550
Anti-Human CD2 (LO-CD2a) – Dylight® 550
Product No.: C541
- -
- -
Clone LO-CD2a Target CD2 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names LFA-2, T11, SRBC, BTI-322 Isotype Rat IgG2b κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Rat Immunogen Purified human T Lymphocytes Product Concentration 2.0 mg/ml Formulation This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Excitation Laser Yellow Laser (563 nm) RRIDAB_2828910 Additional Applications Reported In Literature ? FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2. Background Human CD2 is a 351 amino acid transmembrane glycoprotein that is part of the immunoglobulin superfamily1, 2. CD2 is expressed on the surface of mature T cells, most NK cells, thymocytes, dendritic cells, and 9-12% of bone marrow cells. CD2 participates in T cell and NK cell activation and is important for thymocyte development and assembly of the immunological synapse1. However, the role of CD2 in murine immunity is not always consistent with its function in higher animals. CD2 is known to bind to lymphocyte-associated antigen3 (CD58 and its murine analog CD48) as well as CD59. LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation3, 4. LO-CD2a strongly inhibits mixed lymphocyte culture3 and induces T cell apoptosis5. Additionally, LO-CD2a induces very low levels of cytokine release, inhibits cytokine production induced by OKT3, and induces human T cell hyporesponsiveness3. The immune response is inhibited as a result of cell lysis by antibody-dependent cell mediated cytotoxicity (ADCC) induced by NK cells and activated monocytes and from CD2 down-modulation on CD2+ cells6. LO-CD2a also strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3. LO-CD2a has demonstrated immunosuppressive activity in vitro and effective T cell depletion in vivo. Unresponsiveness upon restimulation with the same antigen makes LO-CD2 distinct from other anti-CD2 antibodies7. Antigen Distribution CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells. Ligand/Receptor CD58 (LFA-3), CD48, CD59, CD15 PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology References & Citations1. Binder C, Cvetkovski F, Sellberg F, et al. Front Immunol. 11:1090. 2020. 2. Bierer BE, Sleckman BP, Ratnofsky SE, et al. Annu Rev Immunol. 7:579–599. 1989. 3. Latinne D, De La Parra B, Nizet Y, et al. Int Immunol. 8(7):1113-1119. 1996. 4. Bazin H, Latinne D, et al, inventors; Biotransplant Inc, assignee. LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation. US patent 6,849,258 B1. Feb 1, 2005. 5. Dumont C, Déas O, Mollereau B, et al. J Immunol. 160(8):3797-3804. 1998. 6. Nizet Y, Chentoufi AA, de la Parra B, et al. Transplantation. 69(7):1420-1428. 2000. 7. Xu Y, Kolber-Simonds D, Hope JA, et al. Clin Exp Immunol. 138(3):476-483. 2004. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
C530 | |
C537 | |
C538 | |
C539 | |
C540 | |
C541 | |
C542 | |
C543 | |
C509 | |
C529 |
![Disclaimer Alert Disclaimer Alert](/wp-content/themes/Avada-Child-Theme/disclaimer.jpg)